Bad blood: secrets and lies in a Silicon Valley startup
(Book)
Author:
Published:
New York : Alfred A. Knopf, 2018.
Format:
Book
Edition:
First edition.
Physical Desc:
x, 339 pages ; 25 cm
Status:
East Hampton Adult Nonfiction
338.7 CAR
Description
"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--
Copies
Location
Call Number
Status
East Hampton Adult Nonfiction
338.7 CAR
On Shelf
Location
Call Number
Status
Bethany/Clark Adult Collection
338.7 CAR
On Shelf
Bill (LPL) Nonfiction
338.7681 Car
On Shelf
Branford/Blackstone Adult Nonfiction
338.7681 CAR
On Shelf
Durham Adult Non-Fiction
338.7681 CARREYROU
On Shelf
East Haddam/Rathbun A Adult Nonfiction
338.7 CAR
On Shelf
East Lyme Public Adult Non-Fiction
338.7681 Carreyrou
On Shelf
Essex Adult Nonfiction
338.7 CAR
In Transit
Guilford Adult Non-Fiction
338.7 CARREYROU
Billed
Haddam/Brainerd Adult Nonfiction
338.7 CAR
Storage
Hamden/Miller Adult Nonfiction 3rd Floor
338.768/CAR
On Shelf
Lyme Adult Nonfiction
338.7 CAR
On Shelf
Madison/Scranton Adult Nonfiction
338.7681 CARREYOU
On Shelf
New London Adult Non Fiction
338.7 CAR
On Shelf
North Stonington/Wheeler Adult Nonfiction
338.7 CARREYROU (OCT 18)
On Shelf
Norwich/Otis Adult Nonfiction
338.47004 CAR
On Shelf
Old Lyme A Non-Fiction 300
338.7681 CAR
On Shelf
Old Saybrook/Acton Adult Non-Fiction
338.7 CARREYROU
On Shelf
Orange/Case Adult Nonfiction Book
338.768 Carreyrou
On Shelf
Wallingford Adult Nonfiction
338.7681 CARREYROU
On Shelf
West Haven Main Adult Non-fiction
338.7681 CARREYROU
On Shelf
Westbrook Adult Non-Fiction
338.7 CAR
On Shelf
Woodbridge Adult NF 300-399
338.47004/CAR
On Shelf
More Details
Language:
English
ISBN:
9781524731656
Notes
Bibliography
Includes bibliographical references (pages 305-324) and index.
Description
"The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"--,Provided by publisher.
Reviews from GoodReads
Loading GoodReads Reviews.
Citations
APA Citation (style guide)
Carreyrou, J. (2018). Bad blood: secrets and lies in a Silicon Valley startup. First edition. Alfred A. Knopf.
Chicago / Turabian - Author Date Citation (style guide)Carreyrou, John. 2018. Bad Blood: Secrets and Lies in a Silicon Valley Startup. Alfred A. Knopf.
Chicago / Turabian - Humanities Citation (style guide)Carreyrou, John, Bad Blood: Secrets and Lies in a Silicon Valley Startup. Alfred A. Knopf, 2018.
MLA Citation (style guide)Carreyrou, John. Bad Blood: Secrets and Lies in a Silicon Valley Startup. First edition. Alfred A. Knopf, 2018.
Note! Citation formats are based on standards as of July 2022. Citations contain only title, author, edition, publisher, and year published. Citations should be used as a guideline and should be double checked for accuracy.
Staff View
Grouped Work ID:
baef1559-c66a-350a-94da-a1c38154f67e
Record Information
| Last Sierra Extract Time | Jul 03, 2025 12:55:29 PM |
|---|---|
| Last File Modification Time | Jul 03, 2025 12:55:50 PM |
| Last Grouped Work Modification Time | Jul 05, 2025 10:18:25 PM |
MARC Record
| LEADER | 05110pam a2200625 i 4500 | ||
|---|---|---|---|
| 001 | ocn2018000263 | ||
| 003 | DLC | ||
| 005 | 20250210224740.0 | ||
| 008 | 180316s2018 nyu e b 001 0 eng | ||
| 010 | |a 2018000263 | ||
| 020 | |a 9781524731656 | ||
| 040 | |a DLC |b eng |e rda |c DLC |d GCmBT | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 100 | 1 | |a Carreyrou, John, |e author. |0 http://id.loc.gov/authorities/names/n2018014999 | |
| 245 | 1 | 0 | |a Bad blood : |b secrets and lies in a Silicon Valley startup / |c John Carreyrou. |
| 246 | 3 | 0 | |a Bad blood |
| 250 | |a First edition. | ||
| 264 | 1 | |a New York : |b Alfred A. Knopf, |c 2018. | |
| 300 | |a x, 339 pages ; |c 25 cm | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a unmediated |b n |2 rdamedia | ||
| 338 | |a volume |b nc |2 rdacarrier | ||
| 504 | |a Includes bibliographical references (pages 305-324) and index. | ||
| 520 | |a "The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley"-- |c Provided by publisher. | ||
| 600 | 1 | 0 | |a Holmes, Elizabeth Anne, |d 1984- |
| 610 | 2 | 0 | |a Theranos (Firm) |x History. |
| 650 | 0 | |a Hematologic equipment industry |z United States. | |
| 650 | 0 | |a New business enterprises |x Corrupt practices |z United States |v Case studies. | |
| 650 | 0 | |a Securities fraud |z United States |v Case studies. | |
| 907 | |a .b25813183 | ||
| 945 | |y .i61252165 |i 22801512678 |l ehan |s - |h |u 24 |x 0 |w 1 |v 1 |t 2 |z 05-23-18 |r - |o - |a 338.7 CAR | ||
| 945 | |y .i61330012 |i 21802529269 |l wdan3 |s - |h |u 32 |x 1 |w 0 |v 18 |t 2 |z 06-08-18 |r - |o - |a 338.47004/CAR | ||
| 945 | |y .i61345246 |i 31200080839300 |l hmanb |s - |h |u 42 |x 3 |w 3 |v 7 |t 2 |z 06-12-18 |r - |o - |a 338.768/CAR | ||
| 945 | |y .i61428012 |i 22702118138 |l duan |s - |h |u 25 |x 0 |w 1 |v 11 |t 2 |z 06-28-18 |r - |o - |a 338.7681 CARREYROU | ||
| 945 | |y .i61431898 |i 20503579482 |l guan |s n |h 12-09-20 |u 20 |x 0 |w 0 |v 1 |t 2 |z 06-28-18 |r - |o - |a 338.7 CARREYROU | ||
| 945 | |y .i61443712 |i 21707538688 |l waan |s - |h |u 31 |x 0 |w 0 |v 15 |t 2 |z 07-03-18 |r - |o - |a 338.7681 CARREYROU | ||
| 945 | |y .i61444194 |i 31251004036481 |l wman |s - |h |u 16 |x 0 |w 0 |v 3 |t 167 |z 07-03-18 |r - |o - |a 338.7681 CARREYROU | ||
| 945 | |y .i61455556 |i 21203821695 |l nwan |s - |h |u 27 |x 1 |w 0 |v 4 |t 2 |z 07-05-18 |r - |o - |a 338.47004 CAR | ||
| 945 | |y .i61466724 |i 20702856996 |l bran |s - |h |u 37 |x 3 |w 2 |v 15 |t 2 |z 07-09-18 |r - |o - |a 338.7681 CAR | ||
| 945 | |y .i61473613 |i 21302194440 |l nlan |s - |h |u 17 |x 0 |w 0 |v 2 |t 2 |z 07-10-18 |r - |o - |a 338.7 CAR | ||
| 945 | |y .i61480265 |i 20802636686 |l lban |s - |h |u 19 |x 1 |w 0 |v 6 |t 2 |z 07-11-18 |r - |o - |a 338.7681 Car | ||
| 945 | |y .i61491536 |i 22001457963 |l olan3 |s - |h |u 22 |x 1 |w 0 |v 3 |t 2 |z 07-13-18 |r - |o - |a 338.7681 CAR | ||
| 945 | |y .i61495414 |i 21501094797 |l exan |s t |h |u 28 |x 1 |w 1 |v 1 |t 2 |z 07-13-18 |r - |o - |a 338.7 CAR | ||
| 945 | |y .i61565635 |i 20603420686 |l elan |s - |h |u 21 |x 0 |w 0 |v 12 |t 2 |z 07-30-18 |r - |o - |a 338.7681 Carreyrou | ||
| 945 | |y .i61714331 |i 33520001291531 |l osan |s - |h |u 27 |x 0 |w 0 |v 9 |t 2 |z 08-31-18 |r - |o - |a 338.7 CARREYROU | ||
| 945 | |y .i63101506 |i 36439000988285 |l haan |s q |h |u 7 |x 0 |w 0 |v 3 |t 2 |z 07-23-19 |r - |o - |a 338.7 CAR | ||
| 945 | |y .i63219931 |i 21600822015 |l wsan |s - |h |u 10 |x 0 |w 2 |v 4 |t 2 |z 08-21-19 |r - |o - |a 338.7 CAR | ||
| 945 | |y .i6345175x |i 33300000756101 |l raan |s - |h |u 9 |x 0 |w 0 |v 2 |t 2 |z 10-15-19 |r - |o - |a 338.7 CAR | ||
| 945 | |y .i64692814 |i 22205158185 |l maan |s - |h |u 11 |x 1 |w 2 |v 1 |t 2 |z 10-09-20 |r - |o - |a 338.7681 CARREYOU | ||
| 945 | |y .i65551679 |i 34362000900856 |l bea |s - |h |u 3 |x 0 |w 0 |v 2 |t 2 |z 06-08-21 |r - |o - |a 338.7 CAR | ||
| 945 | |y .i66112357 |i 35999000658213 |l nsan |s - |h |u 1 |x 0 |w 0 |v 1 |t 2 |z 09-22-21 |r - |o - |a 338.7 CARREYROU (OCT 18) | ||
| 945 | |y .i68798532 |i 32159002248132 |l oran |s - |h |u 7 |x 6 |w 1 |v 3 |t 2 |z 09-20-23 |r - |o - |a 338.768 Carreyrou | ||
| 945 | |y .i69299249 |i 34342001311022 |l lyan |s - |h |u 0 |x 0 |w 0 |v 0 |t 2 |z 12-19-23 |r - |o - |a 338.7 CAR | ||
| 998 | |e - |d a |f eng |a be |a lb |a br |a du |a ra |a eh |a el |a ex |a gu |a ha |a hm |a ly |a ma |a me |a nl |a ns |a nw |a ol |a os |a or |a wa |a wm |a ws |a wd | ||